Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
A new generation of heated tobacco products (HTPs) is being widely promoted in traditional (billboards, print) and social media in Germany. In Germany, HTPs are considered distinct from cigarettes or electronic cigarettes1; bear a 33% lower tax burden than cigarettes2–4 and unlike the graphical health warnings required on cigarette packaging,5 only require a written warning.6
Philip Morris International’s IQOS entered the German market in June 2016.7–11 British American Tobacco’s glo,12–14 followed 4 years later and has taken what appears to be a young target marketing approach. Though later to market, glo is showing greater popularity and traction than IQOS on social media (figure 1). This industry watch examines glo’s marketing approach.
Contributors KG conceptualised the paper. HF conducted the social media scan and collected the social media marketing activities. KG, HF and JJP contributed to the interpretation and write up of the manuscript and approved the final manuscript.
Funding This work was supported by a postdoctoral fellowship training grant from the National Heart, Lung, and Blood Institute (T32HL007034).
Competing interests JJP reports personal fees from Plaintiff Law Firms in lawsuits against the tobacco companies, from Achieve Life Sciences, and from Carrot, for consulting outside the submitted work.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.